Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM

Fig. 1

LINC01852 is frequently downregulated in CRC and is inversely associated with patient prognosis. (A) The expression of LINC01852 in CRC cohort 1 (110 NCTs and 110 CRC tissues) was measured using qRT-PCR. Changes in LINC01852 expression (more than 1.5-fold) in paired samples are depicted in the pie chart. (B) Kaplan-Meier survival analyses with the log-rank tests were performed to investigate the effects of LINC01852 expression on overall survival and disease-free survival in CRC cohort 1. CRC samples were grouped based on the median expression of LINC01852. (C) The expression of LINC01852 in CRC cohort 2 (73 NCTs and 85 CRC tissues) was measured using qRT-PCR. (D) Kaplan-Meier survival analyses based on LINC01852 expression in CRC cohort 2. (E) Univariate and multivariate Cox proportional hazard regression analyses were performed to evaluate the associations between the prognostic factors and overall survival in CRC patients in CRC cohorts 1 and 2

Back to article page

Molecular Cancer

ISSN: 1476-4598